Protein S Human

Summary

Protein S Human (CHEMBL6068491) is an approved protein; indicated across 1 condition including coagulation protein disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Indications: 1 condition
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068491
Name	Protein S Human
Type	Protein
Max phase	4

Also known as: Protein s, Protein s human, Protein s human component of balfaxar, PROTEIN S HUMAN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
coagulation protein disease	4	MONDO:0002242

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03589430	Not specified	UNKNOWN	Haemostatic Imbalance in Patients With Chronic Liver Disease
NCT07036809	Not specified	COMPLETED	Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).